New York, February 18, 2015 -- Moody's Investors Service said that Boston Scientific Corporation's announced $600 million settlement with Johnson & Johnson ("JNJ") -- related to a longstanding lawsuit alleging breach of contract over the 2006 acquisition of Guidant Corporation -- is credit negative but does not have an effect on Boston's Baa3 ratings or stable outlook at this time. For further information, please see Moody's Issuer Comment on Boston Scientific on ww.moodys.com.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.